Physical consequences of schizophrenia and its treatment: The metabolic syndrome

Life Sciences

Volumn 71, Issue 3, 2002, Pages 239-257

  Ryan, Martina C M ^a   Thakore, Jogin H ^a  

^a St Vincent's Hospital Ireland   (Ireland)

Author keywords

Abdominal obesity; Autonomic; Cardiovascular; Cortisol; Diabetes; Dyslipidaemia; Insulin; Medication; Metabolic syndrome; Morbidity; Mortality; Neuroleptic; Schizophrenia; Sympathetic; Visceral fat

Indexed keywords

CHLORPROMAZINE; CLOZAPINE; LITHIUM; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; QUINIDINE; THIORIDAZINE; ZIPRASIDONE;

CARDIOTOXICITY; CARDIOVASCULAR DISEASE; DIET; DISEASE ASSOCIATION; DRUG OVERDOSE; EXERCISE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERCORTISOLISM; HYPERLIPIDEMIA; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; LIFESPAN; LIFESTYLE; LIPID STORAGE; METABOLIC DISORDER; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PHENOTYPE; PHYSICAL DISEASE; SCHIZOPHRENIA; SHORT SURVEY; SIDE EFFECT; SYNDROME; WEIGHT GAIN;

EID: 0037036159     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0024-3205(02)01646-6     Document Type: Review

References (148)

1. Mortality in Norwegian mental hospitals from 1916 to 1933
2. Mortality in mental hospitals with especial regard to tuberculosis
3. Excess mortality in schizophrenia and affective disorders: Do suicides and accidental deaths solely account for this excess?
4. Mortality in a cohort of patients with schizophrenia: A record linkage study
5. Mortality in DSM-IIIR schizophrenia
6. Excess mortality of schizophrenia
7. Causes of the excess mortality of schizophrenia
8. Lifetime risk of suicide for affective disorder, alcoholism and schizophrenia
9. The mortality experience of individuals on the Salford case register. I: All-cause mortality
10. Mortality and causes of death in first admitted schizophrenic patients
11. Excess mortality of mental disorder
12. A record-linkage study of mortality and general hospital discharge in patients diagnosed as schizophrenic
13. Incidence of cancer in patients diagnosed as schizophrenic in Denmark
14. Causes of death in schizophrenia and manic-depression
15. Mortality and causes of death in schizophrenic patients in Denmark
16. Schizophrenia and physical disease: A preliminary analysis of data from the Oxford Record Linkage Study
17. The excess mortality among psychiatric patients: The Iowa record-linkage study
18. Mortality in the long-stay population of Dutch mental hospitals
19. Mortality in schizophrenia: A ten-year follow-up based on the Stockholm county in-patient register
20. The unhealthy lifestyle of people with schizophrenia
21. Echocardiographic assessment of schizophrenics and manics: A re-examination of early necropsy findings
22. Interfaces of Psychopharmacol. and cardiology - Part two: Review article
23. Study of mortality in schizophrenia and neurosis
24. Hsieh. Physical activity, all-cause mortality and longevity of college alumni
25. Smoking and malignancy in schizophrenia
26. Mortality in psychiatric patients, with a specific focus on cancer mortality associated with schizophrenia
27. Substance abuse in schizophrenia
28. Medical disorders in the schizophrenic patient
29. Physical health of the long- term mentally ill in the community: Is there unmet need?
30. Cardiovascular and respiratory risk factors and symptoms among general practice patients with long-term mental illness
31. The distribution of body mass index among individuals with and without schizophrenia
32. Abdominal adipose tissue distribution, obesity and risk of cardiovascular disease and death: 13-year follow-up of participants in the study of men born in 1913
33. Distribution of adipose tissue and risk of cardiovascular disease and death: 12-year follow-up of participants in the population study of women in Gotenburg, Sweden
34. Regional distribution of muscle and fat mass in men: New insight in to the risk of abdominal obesity using computed tomography
35. Relationship of body fat distribution to blood pressure, carbohydrate tolerance, and plasma lipids in healthy women
36. Fatness and fat patterns: Associations with plasma lipids and blood pressure in adults 18 to 57 years of age
37. Evidence for a regional component of body fatness in the association with serum lipids in men and women
38. 1989 Relative contributions of obesity and body fat distribution to alterations in glucose and insulin homeostasis
39. Relationship of fat distribution to glucose tolerance: Results of computed tomography in male participants of the normative aging study
40. The influence of body fat distribution on the incidence of diabetes mellitus: 13 years of follow-up of the participants in the study of men born in 1913
41. The association between obesity, adipose tissue distribution and disease
42. Increased visceral fat distribution in drug-naive and drug-free patients with schizophrenia
43. Western nutrition and the insulin resistance syndrome: A link to breast cancer
44. The degree of masculine differentiation of obesities: A factor determining predisposition to diabetes, atherosclerosis, gout and uric calculous disease
45. Banting lecture 1988: Role of insulin resistance in human disease
46. Etiology of the metabolic syndrome: Potential role of insulin resistance, leptin resistance, and other players
47. The metabolic syndrome X
48. Diabetes in schizophrenia and diabetes in non-psychotic medical patients
49. Diabetes and schizophrenia: A preliminary study
50. Mortality and medical co-morbidity among psychiatric patients: A review
51. Diabetes mellitus in schizophrenic patients
52. Biochemical aspects of schizophrenia
53. Medical comorbidity in schizophrenia
54. Persistent tardive dyskinesia and neuroleptic effects on glucose tolerance
55. Family history of type 2 diabetes in schizophrenic patients
56. A study of diabetes mellitus in first degree relatives of diabetic patients
57. The Pathology of Mind
58. Sugar tolerance in dementia praecox and other mental disorders
59. Delayed action of insulin in schizophrenia
60. Resistance to insulin in mentally disturbed soldiers
61. The insulin tolerance test in mental disorders
62. Characteristics of diabetes mellitus in schizophrenic patients
63. Platelet aggregation and dense granule secretion in schizophrenia
64. Prostaglandin E1 suppression of platelet aggregation response in schizophrenia
65. Platelet aggregation response in schizophrenia and prostaglandin E1
66. Neuroleptic effects on platelet aggregation: A study in normal volunteers and schizophrenics
67. Sinus tachycardia and abnormal cardiac rate variation in schizophrenia
68. Pathology of the energy system: An experimental-clinical study of physiological adaptive capacities in a non-patient, a psycho-neurotic and an early paranoid schizophrenic group
69. The effect of pain on the heart rate of normal and schizophrenic individuals
70. Altered balance in the autonomic nervous system in schizophrenic patients
71. Autonomic nervous system activity in acute schizophenia: II relationships to short-term prognosis and clinical state
72. Role of the sympathetic adrenal system in the pathogenesis of the insulin resistance syndrome
73. Central nervous system and peripheral abnormalities: Clues to the understanding of obesity and NIDDM
74. Relation of obesity to sympathetic nervous system activity
75. Blood pressure in relation to obesity, insulin and the hypothalamic-pituitary-adrenal axis in Swedish men
76. The concepts of stress and stress system disorders. Overview of physical and behavioural homeostasis
77. Circadian and sleep-related endocrine rhythms in schizophrenia
78. Diurnal rhythm of plasma beta endorphin, cortisol and growth hormone in schizophrenics as compared to control subjects
79. Raised plasma cortisol concentrations, a feature of drug-free psychotics and not specific for depression
80. The effects of metabolic stress on plasma progesterone in healthy volunteers and schizophrenic patients
81. Drugs and the DST: Need for a reappraisal
82. Abnormal dexamethasone suppression test results in chronic schizophrenic patients
83. Platelet 5-HT levels and hypothalamic-pituitary-adrenal axis activity in schizophrenic patients with positive and negative symptoms
84. Dexamethasone suppression test in positive and negative schizophrenia
85. Hypothalamic-pituitary-adrenal axis function in chronic schizophrenia: Association with clinical features
86. Hypothalamic-pituitary-adrenal axis hyperactivity and psychosis recovery during an 8 year follow-up
87. The corticotropin-releasing-hormone stimulation test in schizophrenia
88. Combined dexamethasone/corticotropin-releasing hormone test in patients with schizophrenia and in normal controls
89. Neurobiological effects of lumbar puncture stress in psychiatric patients and healthy volunteers
90. Selective impairments in the stress response in schizophrenic patients
91. The interactions between hypothalamic-pituitary-adrenal axis activity, testosterone, insulin-like growth factor I and abdominal obesity with metabolism and blood pressure in men
92. Glucocorticoids are counter-regulatory hormones to leptin. Towards an understanding of leptin resistance
93. The regulation of adipose tissue distribution in humans: Review
94. The effect of cortisol on insulin sensitivity in muscle
95. Insulin resistance: A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidaemia and atherosclerotic cardiovascular disease
96. The hypothalamic-pituitary-adrenal axis activity as a predictor of cardiovascular disease, type 2 diabetes and stroke
97. Mortality in schizophrenia. Antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study
98. Life-threatening ventricular arrhythmia (torsade de pointes) after haloperidol overdose
99. Drugs, QT interval abnormalities and ventricular arrhythmias
100. Electrophysiological effects of phenothiazines on canine cardiac fibers
101. QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients
102. Drug-induced torsade de pointes: Incidence, management and prevention
103. QTc prolongation measured by standard 12-lead electrocardiogram is an independent risk factor for sudden death
104. Concentration-related pharmacodynamic effects of thioridazine and its metabolites in humans
105. Precordial QT interval dispersion as a marker of torsade de pointes
106. Long-term treatment with antipsychotic drugs in conventional doses prolonged QTc dispersion, but did not increase ventricular tachyarrhythmias in patients with schizophrenia in the absence of cardiac disease
107. Electrocardiographic changes induced by phenothiazine drugs
108. Electrocardiographic changes, and serum concentrations in thioridazine-treated patients
109. Survey of sudden death associated with the use of antipsychotic or antidepressant drugs: 49 cases in Finland
110. Is QT interval a marker of subclinical atherosclerosis in nondiabetic subjects? The insulin resistance atherosclerosis study (IRAS)
111. QT interval prolongation in type 2 (non-insulin-dependent) diabetic patients with cardiac autonomic neuropathy
112. QTc duration is associated with levels of insulin and glucose intolerance. The zutaphen elderly Study
113. Induction of obesity by psychotropic drugs
114. Occupancy of central neurotransmitter receptors by risperidone, clozapine and haloperidol, measured ex vivo by quantitative autoradiography
115. Chronic treatment with neuroleptic drugs and weight gain
116. Histamine: A new factor in the control of feeding behaviour
117. Body weight and leptin plasma levels during treatment with antipsychotic drugs
118. Clinical guidelines on the identification, evaluation and treatment of overweight and obesity in adults- the evidence report
119. Changes in body weight and longevity
120. Cigarette smoking, weight gain and coronary mortality: Results from the Chicago western electric study
121. Early body size and subsequent weight gain as predictors of breast cancer incidence (Iowa, United States)
122. Association of smoking, body mass and physical activity with risk of prostate cancer in the Iowa 65+ rural health study (United States)
123. Weight changes and risk of ischaemic heart disease for middle- aged and elderly men: An 8-year follow-up in the Copenhagen male study
124. Weight change and risk of heart attack in middle-aged men
125. Relationship between weight change in young adulthood and the risk of NIDDM: The sotetsu study
126. Estimating the consequences of anti-psychotic induced weight gain on health and mortality rate
127. Antipsychotic-induced weight gain: A comprehensive research synthesis
128. Safety of olanzapine
129. Atypical antipsychotics and weight gain-a systematic review
130. New onset diabetes and atypical antipsychotics
131. Different influences of classical antipsychotics and clozapine on glucose-insulin homeostasis in patients with schizophrenia or related psychoses
132. Elevated levels of insulin, leptin and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses
133. Global burden of diabetes, 1995-2025: Prevalence, numerical estimates, and projections
134. The effect of clozapine on glucose metabolism
135. Glucose-insulin metabolism in chronic schizophrenia
136. Chlorpromazine induced diabetes mellitus
137. Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional neuroleptic medications
138. Prevelance of diabetes and impaired glucose tolerance and plasma glucose levels in US population aged 20-74 yrs
139. Elevated serum triglycerides on clozapine resolve with respiridone (abstract)
140. Serum triglyceride levels in patients treated with clozapine
141. Diminished suicidal and aggressive behaviour, high plasma norepinephrine levels, and serum triglyceride levels in chronic schizophrenic patients maintained on clozapine
142. Clozapine-associated elevation in serum triglycerides
143. The effects of clozapine on levels of total cholesterol and related lipids in serum of patients with schizophrenia: A prospective study
144. The impact of clozapine treatment on serum lipids in chronic schizophrenic patients
145. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study
146. Olanzapine increases weight and serum triglyceride levels